Endothelial Effects of Basal Insulin: Detemir Versus Glargine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00699686|
Recruitment Status : Completed
First Posted : June 18, 2008
Last Update Posted : August 17, 2010
Endothelial progenitor cell (EPC) level represents a surrogate marker of cardiovascular risk and an indicator of the ongoing vascular damage. Moreover, EPCs are involved in the pathogenesis of virtually all diabetic complications. Therefore, ways to modulate EPCs are currently considered of utmost importance, especially in high-risk subjects. While many drugs with pleiotropic vasculoprotective effects have shown ability to positively modulate EPCs, there is no data on the effects of specific insulin formulations.
This is a human randomised cross-over comparison trial. The purpose is to compare the effects of two basal insulin analogues (detemir and glargine) added to oral antidiabetic therapy in poorly-controlled type 2 patients with cardiovascular disease on endothelial function and EPC levels.
The aim is to test whether optimized glycemic control with add-on basal insulin analogues improves endothelial damage and regeneration in type 2 diabetes with macroangiopathy and to compare the effects of glargine vs detemir on markers of endothelial damage and regeneration.
EPC level is the most innovative outcome measure of this study and represents the primary endpoint. Endothelial dysfunction/damage, evaluated using soluble markers, will be the secondary outcome. Given the supposed inverse correlation between EPC and endothelial damage, it is expected that EPC increase reflects amelioration in endothelial biology, a result that may have significant clinical implications in this cohort of high-risk patients.
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes Endothelial Dysfunction Cardiovascular Disease||Drug: Glargine Drug: Detemir||Phase 4|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effects of Optimized Glycemic Control Achieved With add-on Basal Insulin Therapy on Indexes of Endothelial Damage and Regeneration in Type 2 Diabetic Patients With Macroangiopathy. A Randomized Cross-over Trial Comparing Detemir vs Glargine|
|Study Start Date :||May 2008|
|Actual Primary Completion Date :||March 2010|
|Actual Study Completion Date :||March 2010|
Active Comparator: Glargine
During this arm/phase patients take subcutaneous glargine daily for 3 months.
Daily bedtime subcutaneous insulin Glargine in individualized doses.
Other Name: Lantus
During this arm/phase, patients take insulin Detemir subcutaneously for 3 months.
Daily bedtime subcutaneous insulin Detemir in individualized doses.
Other Name: Levemir
- Change in endothelial progenitor cell count [ Time Frame: Basal, 3 months, 6 months ]
- Change in markers of endothelial damage [ Time Frame: Basal, 3 months, 6 months ]
- Frequence of hypoglycemias [ Time Frame: during 1st and 2nd arms ]The frequency of hypoglycemia will be reported for patients on glargine or detemir during the 1st and 2nd period of treatment.
- Change in body weight [ Time Frame: After the 1st and 2nd arms ]Change in body weight will be assessed after each arm during treatment with glargine or detemir
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00699686
|Dipartimento di Medicina Clinica e Sperimentale, Divisione di Malattie del Metabolismo|
|Padova, Italy, 35100|
|Principal Investigator:||Angelo Avogaro, M.D.||University of Padova, Medical School|